logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Oncternal Therapeutics, Inc.


USPTO Granted Patents = 16



Trademarks = 1

Forward Citations = 41

Loading Chart...
Loading Chart...

22 inventors (with patents filed for the assignee):

goldMedal James T Dalton (6 out of 102 patents)

silverMedal Duane Douglas Miller (5 out of 119 patents)

bronzeMedal Brian Lannutti (4 out of 20 patents)

4.  Katayoun Jessen (4 out of 8 patents)

5.  James Bradley Breitmeyer (4 out of 4 patents)

6.  Sunjoo Ahn (4 out of 21 patents)

7.  Ramesh Narayanan (3 out of 43 patents)

8.  Wei Li (3 out of 15 patents)

9.  Jean-Michel Andre Vernier (3 out of 56 patents)

10.  Stephen Evan Webber (3 out of 54 patents)

11.  Jin Wang (2 out of 176 patents)

12.  Thamarai Ponnusamy (2 out of 28 patents)

13.  Dong-Jin Hwang (2 out of 23 patents)

14.  Christopher C Coss (2 out of 12 patents)

15.  Charles B Duke (2 out of 13 patents)


16 patents:

1. 12161626 - Uses of indolinone compounds (2024-12-10),
2. 12128026 - Selective androgen receptor degrader (SARD) ligands and methods of use thereof (2024-10-29),
3. 11465987 - Compounds for treatment of cancer (2022-10-11),
4. 11285132 - Uses of indolinone compounds (2022-03-29),
5. 11084811 - Compounds for treatment of cancer (2021-08-10),
6. 10865196 - Compounds for treatment of cancer (2020-12-15),
7. 10849873 - Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy (2020-12-01),
8. 10711008 - Indoline analogs and uses thereof (2020-07-14),
9. 10646470 - Uses of indolinone compounds (2020-05-12),
10. 10597354 - Selective androgen receptor degrader (SARD) ligands and methods of use thereof (2020-03-24),
11. 10351569 - Indoline analogs and uses thereof (2019-07-16),
12. 10159660 - Uses of indolinone compounds (2018-12-25),
13. 9987251 - Indolinone compounds and uses thereof (2018-06-05),
14. 9895352 - Indolinone compounds and uses thereof (2018-02-20),
15. 9822122 - Indoline analogs and uses thereof (2017-11-21),
Company Overview
Oncternal Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer. The company specializes in advancing targeted treatments that address unmet medical needs in hematologic malignancies and solid tumors. Oncternal's research is centered on leveraging its proprietary technologies to create novel drug candidates aimed at improving patient outcomes and enhancing the quality of life for individuals affected by various forms of cancer.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Oncternal Therapeutics, Inc. USPTO Patent Assignee Logo
16 Patents

#361 in San Diego, CA

#4,767 in California

#19,907 in US

#37,788 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Oncternal Therapeutics, Inc.

Forward Citations = 41

22 inventors:

goldMedal James T Dalton (6 out of 102 patents)

silverMedal Duane Douglas Miller (5 out of 119 patents)

bronzeMedal Brian Lannutti (4 out of 20 patents)

4.  Katayoun Jessen (4 out of 8 patents)

5.  James Bradley Breitmeyer (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncternal Therapeutics, Inc.. Retrieved from https://idiyas.com/company/oncternal-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…